Share on StockTwits
 

GlaxoSmithKline (LON:GSK) was downgraded by research analysts at Cowen and Company to a “market perform” rating in a report released on Wednesday, American Banking News reports.

GSK has been the subject of a number of other recent research reports. Analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,750 ($28.73) price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, January 16th. They now have a GBX 1,500 ($24.62) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, January 14th. They now have a GBX 1,750 ($28.73) price target on the stock. Five analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of GBX 1,705.31 ($27.99).

Shares of GlaxoSmithKline (LON:GSK) traded down 0.69% on Wednesday, hitting GBX 1650.00. 6,148,492 shares of the company’s stock traded hands. GlaxoSmithKline has a 52-week low of GBX 556.50 and a 52-week high of GBX 2076.00. The stock’s 50-day moving average is GBX 1600. and its 200-day moving average is GBX 1628.81. The company’s market cap is £79.480 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.